Evidence for metabolic aberrations in asymptomatic persons with type 2 diabetes after initiation of simvastatin therapy

Translational Research

Volumn 166, Issue 2, 2015, Pages 176-187

  Suneja, Manish ^a   Fox, Daniel K ^a   Fink, Brian D ^a   Herlein, Judy A ^a   Adams, Christopher M ^a   Sivitz, William I ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITRATE SYNTHASE; CREATINE KINASE; LOW DENSITY LIPOPROTEIN; SIMVASTATIN; UBIQUINONE; MESSENGER RNA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CREATINE KINASE BLOOD LEVEL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; METABOLIC DISORDER; MITOCHONDRION; MUSCLE BIOPSY; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTING ENERGY EXPENDITURE; VASTUS LATERALIS MUSCLE; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DNA MICROARRAY; DRUG EFFECTS; ENERGY METABOLISM; ENZYMOLOGY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MUSCLE; MUSCLE MITOCHONDRION;

AGED; CITRATE (SI)-SYNTHASE; DIABETES MELLITUS, TYPE 2; ENERGY METABOLISM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; MITOCHONDRIA, MUSCLE; MUSCLES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA, MESSENGER; SIMVASTATIN; UBIQUINONE;

EID: 84937634884     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2015.01.007     Document Type: Article

References (45)

1. Association AD Standards of care. Diabetes care 2008 Available at: www.diabetes.org/home.jsp
2. A.J. Dirks, and K.M. Jones Statin-induced apoptosis and skeletal myopathy Am J Physiol Cell Physiol 291 2006 C1208 C1212
3. K.A. Sewright, P.M. Clarkson, and P.D. Thompson Statin myopathy: incidence, risk factors, and pathophysiology Curr Atheroscler Rep 9 2007 389 396
4. U.C. Tran, and C.F. Clarke Endogenous synthesis of coenzyme Q in eukaryotes Mitochondrion 7 suppl 2007 S62 S71
5. I.P. Hargreaves, A.J. Duncan, S.J. Heales, and J.M. Land The effect of HMG-CoA reductase inhibitors on coenzyme Q10: possible biochemical/clinical implications Drug Saf 28 2005 659 676
6. L. Marcoff, and P.D. Thompson The role of coenzyme Q10 in statin-associated myopathy: a systematic review J Am Coll Cardiol 49 2007 2231 2237
7. H. Paiva, K.M. Thelen, R. Van Coster, and et al. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial Clin Pharmacol Ther 78 2005 60 68
8. S. Larsen, N. Stride, M. Hey-Mogensen, and et al. Simvastatin effects on skeletal muscle: relation to decreased mitochondrial function and glucose intolerance J Am Coll Cardiol 61 2013 44 53
9. C. Lamperti, A.B. Naini, V. Lucchini, and et al. Muscle coenzyme Q10 level in statin-related myopathy Arch Neurol 62 2005 1709 1712
10. M.G. McDonnell, and G.P. Archbold Plasma ubiquinol/cholesterol ratios in patients with hyperlipidaemia, those with diabetes mellitus and in patients requiring dialysis Clin Chim Acta 253 1996 117 126
11. Y. Miyake, A. Shouzu, M. Nishikawa, and et al. Effect of treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on serum coenzyme Q10 in diabetic patients Arzneimittelforschung 49 1999 324 329
12. D. Preiss, S.R. Seshasai, P. Welsh, and et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis JAMA 305 2011 2556 2564
13. N. Sattar, D. Preiss, H.M. Murray, and et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials Lancet 375 2010 735 742
14. R.V. Shah, and A.B. Goldfine Statins and risk of new-onset diabetes mellitus Circulation 126 2012 30 e282 e284
15. B. Zafrir, and M. Jain Lipid-lowering therapies, glucose control and incident diabetes: evidence, mechanisms and clinical implications Cardiovasc Drugs Ther 28 2014 361 367
16. W.I. Sivitz, and M.A. Yorek Mitochondrial dysfunction in diabetes: from molecular mechanisms to functional significance and therapeutic opportunities Antioxid Redox Signal 12 2010 537 577
17. Standards of medical care in diabetes - 2009 Diabetes Care 32 suppl 1 2009 S13 S61
18. D.R. Westenskow, C.A. Schipke, J.L. Raymond, and et al. Calculation of metabolic expenditure and substrate utilization from gas exchange measurements JPEN J Parenter Enteral Nutr 12 1988 20 24
19. M. Merlo Pich, A. Castagnoli, A. Biondi, and et al. Ubiquinol and a coenzyme Q reducing system protect platelet mitochondrial function of transfusional buffy coats from oxidative stress Free Radic Res 36 2002 429 436
20. L. Yu, B.D. Fink, J.A. Herlein, and W.I. Sivitz Mitochondrial function in diabetes: novel methodology and new insight Diabetes 62 2013 1833 1842
21. P. Niklowitz, T. Menke, W. Andler, and J.G. Okun Simultaneous analysis of coenzyme Q10 in plasma, erythrocytes and platelets: comparison of the antioxidant level in blood cells and their environment in healthy children and after oral supplementation in adults Clin Chim Acta 342 2004 219 226
22. M. Pescatori, A. Broccolini, C. Minetti, and et al. Gene expression profiling in the early phases of DMD: a constant molecular signature characterizes DMD muscle from early postnatal life throughout disease progression FASEB J 21 2007 1210 1226
23. X. Suarez-Calvet, E. Gallardo, G. Nogales-Gadea, and et al. Altered RIG-I/DDX58-mediated innate immunity in dermatomyositis J Pathol 233 2014 258 268
24. S.D. Kunkel, M. Suneja, S.M. Ebert, and et al. mRNA expression signatures of human skeletal muscle atrophy identify a natural compound that increases muscle mass Cell Metab 13 2011 627 638
25. K.J. Livak, and T.D. Schmittgen Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method Methods 25 2001 402 408
26. C.S. Fox, S. Coady, P.D. Sorlie, and et al. Trends in cardiovascular complications of diabetes JAMA 292 2004 2495 2499
27. N.J. Stone, J. Robinson, A.H. Lichtenstein, and et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines J Am Coll Cardiol 63 2013 2889 2934
28. P. Sirvent, O. Fabre, S. Bordenave, and et al. Muscle mitochondrial metabolism and calcium signaling impairment in patients treated with statins Toxicol Appl Pharmacol 259 2012 263 268
29. G. De Pinieux, P. Chariot, M. Ammi-Said, and et al. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio Br J Clin Pharmacol 42 1996 333 337
30. P. Sirvent, J. Mercier, G. Vassort, and A. Lacampagne Simvastatin triggers mitochondria-induced Ca2+ signaling alteration in skeletal muscle Biochem Biophys Res Commun 329 2005 1067 1075
31. R. Laaksonen, K. Jokelainen, T. Sahi, M.J. Tikkanen, and J.J. Himberg Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans Clin Pharmacol Ther 57 1995 62 66
32. R. Laaksonen, K. Jokelainen, J. Laakso, and et al. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle Am J Cardiol 77 1996 851 854
33. A.M. Bargossi, G. Grossi, P.L. Fiorella, A. Gaddi, R. Di Giulio, and M. Battino Exogenous CoQ10 supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitors Mol Aspects Med 15 suppl 1994 s187 s193
34. C.R. Mikus, L.J. Boyle, S.J. Borengasser, and et al. Simvastatin impairs exercise training adaptations J Am Coll Cardiol 62 2013 709 714
35. P.S. Phillips, C.T. Phillips, M.J. Sullivan, R.K. Naviaux, and R.H. Haas Statin myotoxicity is associated with changes in the cardiopulmonary function Atherosclerosis 177 2004 183 188
36. J.S. Wu, C. Buettner, H. Smithline, L.H. Ngo, and R.L. Greenman Evaluation of skeletal muscle during calf exercise by 31-phosphorus magnetic resonance spectroscopy in patients on statin medications Muscle Nerve 43 2011 76 81
37. R.C. Pasternak, S.C. Smith Jr., C.N. Bairey-Merz, S.M. Grundy, J.I. Cleeman, and C. Lenfant ACC/AHA/NHLBI Clinical Advisory on the use and safety of statins Stroke 33 2002 2337 2341
38. L.R. Smith, G. Meyer, and R.L. Lieber Systems analysis of biological networks in skeletal muscle function Wiley Interdiscip Rev Syst Biol Med 5 2013 55 71
39. L. Sorokin The impact of the extracellular matrix on inflammation Nat Rev Immunol 10 2010 712 723
40. D.E. Kelley, J. He, E.V. Menshikova, and V.B. Ritov Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes Diabetes 51 2002 2944 2950
41. M. Mogensen, K. Sahlin, M. Fernstrom, and et al. Mitochondrial respiration is decreased in skeletal muscle of patients with type 2 diabetes Diabetes 56 2007 1592 1599
42. E. Link, S. Parish, J. Armitage, and et al. SLCO1B1 variants and statin-induced myopathy - a genomewide study N Engl J Med 359 2008 789 799
43. D.J. Graham, J.A. Staffa, D. Shatin, and et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs JAMA 292 2004 2585 2590
44. J.R. Faust, M.S. Brown, and J.L. Goldstein Synthesis of delta 2-isopentenyl tRNA from mevalonate in cultured human fibroblasts J Biol Chem 255 1980 6546 6548
45. C.F. Schaars, and A.F. Stalenhoef Effects of ubiquinone (coenzyme Q10) on myopathy in statin users Curr Opin Lipidol 19 2008 553 557